These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12487146)

  • 1. In vitro studies in drug discovery and development: an analysis of study objectives and application of good laboratory practices (GLP).
    Bajpai M; Esmay JD
    Drug Metab Rev; 2002 Nov; 34(4):679-89. PubMed ID: 12487146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of high-throughput screening techniques to drug discovery.
    Cox B; Denyer JC; Binnie A; Donnelly MC; Evans B; Green DV; Lewis JA; Mander TH; Merritt AT; Valler MJ; Watson SP
    Prog Med Chem; 2000; 37():83-133. PubMed ID: 10845248
    [No Abstract]   [Full Text] [Related]  

  • 3. Fragment-based drug design: combining philosophy with technology.
    Bartoli S; Fincham CI; Fattori D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):422-9. PubMed ID: 17659483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward.
    Reinhart GA; Fryer RM; Osinski MA; Polakowski JS; Cox BF; Gintant GA
    Curr Opin Chem Biol; 2005 Aug; 9(4):392-9. PubMed ID: 15950522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro preclinical lead optimisation technologies (PLOTs) in pharmaceutical development.
    Atterwill CK; Wing MG
    Toxicol Lett; 2002 Feb; 127(1-3):143-51. PubMed ID: 12052652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hit discovery and hit-to-lead approaches.
    Keseru GM; Makara GM
    Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality management of pharmacology and safety pharmacology studies.
    Spindler P; Seiler JP
    Fundam Clin Pharmacol; 2002 Apr; 16(2):83-90. PubMed ID: 12031061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good Laboratory Practice (GLP) status of Asian countries and its implementation in non-clinical safety studies in pharmaceutical drug development.
    Sasaki M; Hinotsu S; Kawakami K
    J Toxicol Sci; 2009 Oct; 34(5):493-500. PubMed ID: 19797857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Backup programs in drug discovery.
    Greenlee WJ; Desai M
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):412-3. PubMed ID: 16889224
    [No Abstract]   [Full Text] [Related]  

  • 10. Translational research in central nervous system drug discovery.
    Hurko O; Ryan JL
    NeuroRx; 2005 Oct; 2(4):671-82. PubMed ID: 16489374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in multivariate analysis in pharmaceutical process development.
    McKay B; Hoogenraad M; Damen EW; Smith AA
    Curr Opin Drug Discov Devel; 2003 Nov; 6(6):966-77. PubMed ID: 14758764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a new drug--from target identification to ultra-high-throughput screening.
    Golz S; Hüser J
    Clin Lab; 2007; 53(1-2):77-9. PubMed ID: 17323829
    [No Abstract]   [Full Text] [Related]  

  • 13. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies.
    Andrade EL; Bento AF; Cavalli J; Oliveira SK; Schwanke RC; Siqueira JM; Freitas CS; Marcon R; Calixto JB
    Braz J Med Biol Res; 2016 Dec; 49(12):e5646. PubMed ID: 27982281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing a molecular delivery system within a preclinical timeframe.
    Henck JO; Byrn SR
    Drug Discov Today; 2007 Mar; 12(5-6):189-99. PubMed ID: 17331883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hit and Lead identification: efficient practices for drug discovery.
    Goodnow RA; Gillespie P
    Prog Med Chem; 2007; 45():1-61. PubMed ID: 17280901
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline.
    Menshykau D
    Drug Discov Today; 2017 Nov; 22(11):1598-1603. PubMed ID: 28545837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celebrating the SSCI: the drug discovery pathway: challenges and pitfalls.
    Bennett JC
    Am J Med Sci; 2003 Dec; 326(6):329-32. PubMed ID: 14671495
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of high-content analysis for compound screening and target selection.
    Rausch O
    IDrugs; 2005 Jul; 8(7):573-7. PubMed ID: 15973566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical drug discovery research and training at Vanderbilt.
    Lindsley CW; Weaver D; Jones C; Marnett L; Conn PJ
    ACS Chem Biol; 2007 Jan; 2(1):17-20. PubMed ID: 17243778
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.